Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Continues Search For Novel Compounds In Asia, Inking Deal With India's Glenmark For Phase I Biologic

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal is first for a biological candidate from India.
Advertisement

Related Content

Deals Of The Week: NewDrugs4BadBugs Initiative, GSK/Auxilium, DaVita/Healthcare Partners
Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 2 of 2)
Glenmark Steps Closer To First NCE With Positive Phase II Data For Crofelemer; Gears Up For Larger Trials
Sanofi-Aventis Asia Pacific R&D Head Frank Jiang Sees Progress And Promise In Research Alliances Across China
"We Have Gone Through Hardships But Our Passion Remains High," Says Glenn Saldanha, Managing Director, Glenmark Pharma: An Interview With PharmAsia News (Part 2 of 2)
Sanofi-Aventis Enters First R&D Pact In India For Glenmark's Pain Drugs; Instills Optimism In India's R&D Capabilities
Sanofi-Aventis Enters First R&D Pact In India For Glenmark's Pain Drugs; Instills Optimism In India's R&D Capabilities

Topics

Advertisement
UsernamePublicRestriction

Register

PS072242

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel